An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-3995 After a Single Oral Dose to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs MT 3995 (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 29 Jan 2017 Status changed from active, no longer recruiting to completed.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2016 New trial record